Advertisement

Magnetic Resonance Imaging-Guided Interstitial Prostate Brachytherapy

  • Anthony V. D’Amico
  • Kristin Valentine
  • Ferenc Jolesz
  • Lynn Lopes
  • Sanjaya Kumar
  • Clare M. Tempany
  • Robert Cormack
Chapter

Abstract

Adenocarcinoma of the prostate is currently the most commonly diagnosed cancer in men in the United States and the second leading cause of cancer mortality (1). The natural history of treated clinically localized and potentially curable disease is often protracted. As a result, side effects sustained from the primary treatment may persist for extended periods, often several decades. Therefore, it is important that the treatment, whose goal is to permanently eradicate the disease, also have acceptable complication rates, leaving the patient with an acceptable quality of life after therapy is complete. To this end, efforts aimed at providing a minimally invasive alternative to radical prostatectomy (RP) for the curative treatment of patients with clinically localized prostate cancer have been made.

Keywords

Radical Prostatectomy Clinical Target Volume Prostate Gland Volume Localize Prostate Cancer Acute Urinary Retention 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal A, Thomas A, Murray T, Thum M. Cancer statistics 2002. CA Cancer J Clin 2002;52:23–47.PubMedCrossRefGoogle Scholar
  2. 2.
    Ragde H, Blasko JC, Grimm PD, et al. (1997) Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997;80:442–453.CrossRefGoogle Scholar
  3. 3.
    Bice WS Jr, Prestidge BR, Grimm PD, et al. (1998) Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998;41:921–927.CrossRefGoogle Scholar
  4. 4.
    D’Amico AV, Cormack R, Tempany CM, et al. (1998) Real time magnetic resonance image guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1998;42:507–516.CrossRefGoogle Scholar
  5. 5.
    Ragde H, Korb LJ, Elgamal AA, Grado GL, Nadir BS. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow up. Cancer 2000;89:135–141.PubMedCrossRefGoogle Scholar
  6. 6.
    Cancer, Manual for Staging Cancer, 4th edition. Philadelphia, JP Lippincott, 1997.Google Scholar
  7. 7.
    Gleason DF and the Veterans Administration Cooperative Urological Research Group. Histologic grading and staging of prostatic carcinoma, in Urologic Pathology (Tannenbaum M, ed.). Philadelphia, Lea & Febiger; 1977; pp. 171–187.Google Scholar
  8. 8.
    D’Amico AV, Whittington R, Malkowicz SBK, et al. Endorectal magnetic resonance imaging as a predictor of biochemical outcome following radical prostatectomy for men with clinically localized prostate cancer. J Urol 2000;164:759–763.PubMedCrossRefGoogle Scholar
  9. 9.
    D’Amico AV, Cormack RA, Tempany CM. MRI-guided diagnosis and treatment of prostate cancer. N Engl J Med 2001;344:776–777.PubMedCrossRefGoogle Scholar
  10. 10.
    Lee AK, Schultz D, Renshaw AA, Richie JP, D’Amico AV. Optimizing patient selection for prostate monotherapy. Int J Radiat Oncol Biol Phys 2001;49:673–677.PubMedCrossRefGoogle Scholar
  11. 11.
    Talcott JA, Reiker P, Propert KJ, et al. Patient reported impotence and incontinence after nerve-sparing radical prostatectomy. J Nall Cancer Inst 1997;89:1117–1123.CrossRefGoogle Scholar
  12. 12.
    Jolesz FA. Image-guided procedures and the operating room of the future. Radiology 1997;204:601–612.PubMedGoogle Scholar
  13. 13.
    Wallner K, Roy J, Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1995;32:465–471.PubMedCrossRefGoogle Scholar
  14. 14.
    Cormack RA, Tempany CM, D’Amico AV. A clinical method for real-time dosimetric guidance of transperineal I-125 prostate implant using IMRI imaging. Int J Radiat Oncol Biol Phys 2000;46:210–217.CrossRefGoogle Scholar
  15. 15.
    Nath R, Anderson LL, Luxton G, Weaver K, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys 1995;22:209–234.PubMedCrossRefGoogle Scholar
  16. 16.
    Thomas MD, Cormack R, Tempany CM, et al. Identifying the predictors of acute urinary retention following magnetic-resonance image guided prostate brachytherapy. Int J Radiat Oncol Biol Phys2000;47:905–908.CrossRefGoogle Scholar
  17. 17.
    Simultaneous inferences and other topics in regression analysis-1, in Applied Linear Regression models, 1st ed (Neter J, Wasserman W, and Kutner M, eds.) Homewood, IL: Richard n. Irwin, Inc..: pp. 150–153.Google Scholar
  18. 18.
    D’Amico AV, Whittington R, Malkowicz SB, et al. The clinical utility of the percent of positive prostate biopsies in defining biochemical outcome following radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000;18:11641172.PubMedGoogle Scholar
  19. 19.
    D’Amico AV, Schultz D, Silver B, et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2001;49:679–684.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. Totowa, NJ 2003

Authors and Affiliations

  • Anthony V. D’Amico
  • Kristin Valentine
  • Ferenc Jolesz
  • Lynn Lopes
  • Sanjaya Kumar
  • Clare M. Tempany
  • Robert Cormack

There are no affiliations available

Personalised recommendations